Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Wayne Ngo
Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells
Abstract Primary human myeloid cells hold promise for immunotherapies, yet efficient, scalable technologies for engineering and screening in these cells remain limited. Here we present a virus-like particle (VLP)-based toolkit that delivers diverse CRISPR editing modalities to human monocytes, macrophages and dendritic cells with high efficiency while preserving viability and innate immune responsiveness.
Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding
|
Correction to: Nature https://doi.org/10.1038/s41586-026-10738-7 Published online 8 June 2026 In the version of this article initially published, in Fig. 4c, the label currently reading “TP53R280K transcript” appeared originally as “TP53R248Q transcript.” The figure is amended in the HTML and PDF versions of the article. About this article Zeng, J., Cheng, Z., Chen, H. et al. Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding. Nature (2026).
By Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, Daniel Rosas-Rivera, Zeyuan Zhang, Min Hyung Kang, Ying Mao, Morgan E. Diolaiti, Giselle Lee, John F. X. Diffley, Yixuan Song, Longhui Qiu, Nathan M. Krah, Niren Murthy, Ryan Jackson, Yang Liu Verified, Alan Ashworth Verified, Jennifer Doudna
|
Nature
Verified
Targeting cancer-specific mutations with RNA-triggered chromatin shredding
|
Abstract Genetic mutations that drive cancer often occur in tumour-suppressor proteins such as the p53 transcription factor, which is altered in 40–50% of cases1,2. However, current therapies often fail to target these mutations because the mutant proteins typically lack defined drug-binding pockets and restoring their endogenous function has proven challenging.
By Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, Daniel Rosas-Rivera, Zeyuan Zhang, Min Hyung Kang, Ying Mao, Morgan E. Diolaiti, Giselle Lee, John F. X. Diffley, Yixuan Song, Longhui Qiu, Nathan M. Krah, Niren Murthy, Ryan Jackson, Yang Liu, Alan Ashworth Verified, Jennifer Doudna
|
Nature
Verified
Adjunctive IlluminOss Fixation for a Vancouver B1 Periprosthetic Femoral Fracture: A Case Report
Specialty Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional.
In vivo site-specific engineering to reprogram T cells
|
Abstract Engineered T cells, reprogrammed to express chimeric antigen receptors (CAR) or T cell receptors (TCR), have transformed cancer treatment and are being explored as therapeutics for autoimmune and infectious diseases. Enhancing T cell function through genome editing, either by disrupting endogenous genes or precisely inserting DNA payloads, has shown considerable promise1. However, the ex vivo manufacturing process is lengthy and costly, limiting accessibility of these therapies.
By William A Nyberg, Pierre-Louis Bernard, Wayne Ngo, Charlotte Wang, Jonathan Ark, Allison Rothrock, Gina M. Borgo, Gabriella R. Kimmerly, Jae Hyung Jung, Vincent Allain, Jennifer Hamilton, Alisha Baldwin, Robert R. Stickels, Sarah Wyman, Safwaan H. Khan, Shanshan Lang, Donna Marsh, Niran Almudhfar, Catherine Novick, Yasaman Mortazavi, Shimin Zhang, Mahmoud M. AbdElwakil, Luis Sandoval, Sidney Hwang, Simon Chu, Hyuncheol Jung, Chang Liu, Devesh Sharma, Travis McCreary, Zhongmei Li, Ansuman T. Satpathy, Julia Carnevale, Rachel L Rutishauser, M. Kyle Cromer, Kole T. Roybal, Stacie E. Dodgson, Jennifer Doudna, Aravind Asokan, Justin Eyquem
|
Nature
Verified
Targeted delivery of genome editors in vivo - Nature Biotechnology
Abstract Genome editing has revolutionized the treatment of genetic diseases, yet the difficulty of tissue-specific delivery currently limits applications of editing technology. In this Review, we discuss preclinical and clinical advances in delivering genome editors with both established and emerging delivery mechanisms.
Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - Nature Chemical Biology
Abstract Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both outside and inside of cells.
Discovering nanoparticle corona ligands for liver macrophage capture - Nature Nanotechnology
Abstract Liver macrophages capture circulating nanoparticles and reduce their delivery to target organs. Serum proteins adsorb to the nanoparticle surface after administration. However, the adsorbed serum proteins and their cognate cell receptors for removing nanoparticles from the bloodstream have not been linked. Here we use a multi-omics strategy to identify the adsorbed serum proteins binding to specific liver macrophage receptors.
Cellular Glycocalyx Affects Nanoparticle Access to Cell Membranes and Uptake
Conflict of Interest W.C.W.C. consults for Metis Therapeutics, Merck, Moderna, Foresight Ventures, Luna Nanotech, and Cystic Fibrosis Foundation. Supporting Information Filename Description adma202503004-sup-0001-SuppMat.docx1.3 MB Supporting Information References 1, , , , , , Nat. Rev. Drug Discovery 2021, 20, 101. 2, Structure of the Plasma Membrane, Sinauer Associates, Sunderland, MA, 2000. 3, in International Review of Cytology, Elsevier, Amsterdam 1970, p. 29. 4, , , , , , , , , Sci. Rep.
The pathways for nanoparticle transport across tumour endothelium - Nature Nanotechnology
Abstract The active transport and retention principle is an alternative mechanism to the enhanced permeability and retention effect for explaining nanoparticle tumour delivery. It postulates that nanoparticles actively transport across tumour endothelial cells instead of passively moving through gaps between these cells. How nanoparticles transport across tumour endothelial cells remains unknown.
Mechanism-guided engineering of a minimal biological particle for genome editing
Abstract The widespread application of genome editing to treat or even cure disease requires the delivery of genome editors into the nucleus of target cells. Enveloped Delivery Vehicles (EDVs) are engineered virally-derived particles capable of packaging and delivering CRISPR-Cas9 ribonucleoproteins (RNPs). However, the presence of lentiviral genome encapsulation and replication components in EDVs has obscured the underlying delivery mechanism and precluded particle optimization.
The mechanisms of nanoparticle delivery to solid tumours - Nature Reviews Bioengineering
Abstract Nanoparticles for the detection and treatment of cancer have suffered from limited clinical translation. A key problem has been the lack of understanding of the mechanisms of nanoparticle delivery to solid tumours. The current delivery mechanism is called the enhanced permeability and retention effect, which states that nanoparticles passively enter the tumour through gaps between endothelial cells and are retained because of poor lymphatic drainage.
The exit of nanoparticles from solid tumours - Nature Materials
Abstract Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels impair the exit of nanoparticles and lead to enhanced retention. Here we show that nanoparticles exit the tumour through the lymphatic vessels within or surrounding the tumour. The dominant lymphatic exit mechanism depends on the nanoparticle size.
DNA-Controlled Encapsulation of Small Molecules in Protein Nanoparticles
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Am. Chem. Soc. 2020, XXXX, XXX Wednesday, October 7, 3:00AM - 2:00PM ET Please be aware that pubs.acs.org is undergoing maintenance that may have an impact on your account functions. During this time, you may not be able to log-in to access your subscribed content, purchase single articles, or modify your e-Alert preferences. We appreciate your patience as we continue to improve the ACS Publications platform.
A framework for designing delivery systems
Abstract The delivery of medical agents to a specific diseased tissue or cell is critical for diagnosing and treating patients. Nanomaterials are promising vehicles to transport agents that include drugs, contrast agents, immunotherapies and gene editors. They can be engineered to have different physical and chemical properties that influence their interactions with their biological environments and delivery destinations.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Wayne
Contact Wayne, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack